The Federal Trade Commission Sued to Block the $3.5 Billion Merger of the Two Biggest Vet Suppliers

If the court agrees, clinics keep the price war that has held down their supply costs — and pet owners keep the benefit.

Sources

Sources & evidence

What “Source checked” means

CORLatest quote

The Federal Trade Commission sued on Friday to block Covetrus from buying MWI Veterinary Supply for $3.5 billion, saying the deal would merge the two largest veterinary suppliers.

The lawsuit, filed in federal court in New York, asks for a permanent injunction, a court order blocking the deal permanently. Thirteen state attorneys general joined the complaint alongside the federal agency.

Covetrus is owned by Clayton, Dubilier & Rice and TPG, two investment firms. It would acquire MWI from its parent, Cencora, under a deal first agreed in February.

Two markets, and two leaders in each

The complaint defines two markets: distribution to veterinary clinics, and distribution to large corporate accounts. In each market, the Federal Trade Commission says, Covetrus and MWI are the two largest suppliers.

Both supply the goods clinics use every day, from pharmaceuticals and vaccines to gloves, gauze and syringes. They also supply surgical supplies and thousands of other products, along with related services.

Their customers range from single-veterinarian practices to corporate groups with hundreds of clinic locations. Both run national networks of distribution centers, the complaint says, and offer discounts and rebates that smaller rivals cannot match.

Merging them, the complaint alleges, would drive up costs for clinics and lower service quality. The cost would then reach pet owners as higher prices, according to the complaint.

"Veterinarians and millions of American pet owners benefit when veterinary distributors compete by offering lower prices and better service," said Daniel Guarnera, who directs the competition bureau at the Federal Trade Commission. "This transaction will reduce competition in an already concentrated market and drive up prices for veterinarians and their customers."

"These two companies are engaged in fierce head-to-head competition, and Covetrus wants to eliminate its closest competitor rather than compete for veterinary clinic customers," Guarnera said.

A price war the complaint says the deal would end

The complaint describes years of direct rivalry that it calls an all-out price war. When MWI cut prices aggressively, Covetrus lowered its own prices in response, the complaint says.

Covetrus also offered rebates through VetSuite, its program for veterinary practices. Competition sharpened further after Vetcove emerged, the complaint says.

Vetcove is an online platform where veterinarians compare prices across distributors. A clinic can use one distributor's lower price as leverage against the other in negotiations.

New rivals would struggle to break in, the complaint alleges, because the market's structure blocks entry. Specialty distributors, manufacturers and retailers supply some products, it says, but none meaningfully constrains the two leaders.

The combination would leave both markets highly concentrated, the complaint says. It calls the deal presumptively unlawful under current antitrust case law and the merger guidelines the commission shares with the Department of Justice.

Presumptively unlawful means the law treats the deal as illegal unless the companies prove otherwise. That is the legal ground on which the commission asks the court to stop the acquisition.

Covetrus says the case misreads how veterinarians buy

Covetrus said in its own statement that the case rests on a narrow and outdated view of the market. The lawsuit, the statement said, "does not reflect an accurate understanding of how veterinarians actually buy the products they need."

The merger stands to improve the economics of veterinary practices, Covetrus said in the same statement. Combining the two would make it easier and more efficient for veterinarians to reach the products they need.

Covetrus called itself confident in the merits of the transaction and fully prepared to defend them in court. In February, its chief executive, Ben Wolin, had cast the combination differently, as a way to make animal healthcare more affordable and accessible.

The February deal always needed regulatory approval

Cencora and Covetrus agreed the merger in February, creating a combined animal-health platform. The deal values MWI at $3.5 billion in total, above the value Cencora carries for the business on its books.

On closing, Cencora would receive $1.25 billion in cash and $800 million in preferred equity. It would also receive $1.45 billion in common equity, leaving it with a non-controlling stake of 34.3 percent in the combined company.

Completion was always subject to customary closing conditions, including receipt of required regulatory approvals. Cencora reaffirmed its fiscal 2026 guidance in February, guidance that never assumed a closing in the year ending September 30, 2026.

Bob Mauch, the chief executive of Cencora, said in February the deal puts MWI with a partner dedicated to animal health. It also lets Cencora invest in its key growth priorities, he said.

What remains unknown

Whether a court blocks the deal is unknown. The commission voted 2-0 to authorize its staff to seek that injunction, and a federal judge must still decide whether to grant it.

What Cencora itself thinks is unknown from the reports checked for this article. Cencora had not responded to requests for comment in the Reuters and Dow Jones reports.

How clinics would fare without the deal is also unknown. The complaint predicts higher costs and weaker service from a merger, while Covetrus predicts better practice economics, and neither claim has been tested in court.

The settled market verdict is unknown. Reuters put Cencora shares up about two percent in midday trading on Friday, an intraday reading only, so Friday's closing price is the first settled verdict.

What happens next runs through the court

The two companies have already agreed to a temporary restraining order, a short-term court order, that prevents them from completing the merger before December 4, 2026. Attorney General Letitia James and the coalition are seeking a preliminary injunction to further halt the merger, and ultimately a ruling declaring the merger illegal.

The case now sits in the United States District Court for the Southern District of New York. Thirteen states joined the complaint: Arizona, Arkansas, California, Colorado, Maine, Michigan, Minnesota, Nebraska, New York, North Carolina, Ohio, Oregon and Texas.

Analysts at J.P. Morgan, cited by Reuters, do not expect the challenge to hurt Cencora's forecast. They expect Cencora to press the deal on its strategic merits, Reuters reported.

If the sale is ultimately blocked, the same analysts expect Cencora would likely look for alternative transactions for MWI. The December 4 deadline, the injunction fight and that alternative path are the checks that matter next.

Sources & evidence

Source checked5 sources · 8 figures

Figure receipts

Every figure in this article, with the source it came from.

  • $3.5B Transaction value for MWI Veterinary Supply (enterprise value)

    As of Nov. 13, 2026

  • $1.25B Upfront cash Cencora would receive on closing

    As of Nov. 13, 2026

  • $800M Preferred equity Cencora would receive on closing

    As of Nov. 13, 2026

  • $1.45B Common equity Cencora would receive on closing

    As of Nov. 13, 2026

  • 34.3 Non-controlling common equity stake Cencora would retain in the combined company

    % · As of Nov. 13, 2026

  • 13 States whose attorneys general joined the complaint

    states · As of Nov. 13, 2026

  • 2 Commission votes authorizing staff to seek a permanent injunction (none against)

    votes · As of Nov. 13, 2026

  • 2 Rise in Cencora shares in midday trading on Friday, November 13, 2026, as reported by Reuters (intraday only)

    % · As of Nov. 13, 2026

All dates 2026.

TickerGrove house illustration for healthcare coverage: a double helix

Get the Morning Brief — Weekday Morning Brief · Saturday Weekend Brief · Sunday Week Ahead

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

Disclaimer

TickerGrove is education and journalism only. It is not investment advice, not a broker-dealer, and not a recommendation to buy, sell, or hold any security.

Nothing on this site is a pick or a return promise. Official economic prints and company filings are dated observations. External quote links open a separate service; TickerGrove does not host those prices.

Markets · All stories